NACL Industries Share Price Today

NACL Industries executes agreement to divest Nasense Labs stake

NACL Industries Limited finalized the divestment of its stake in associate company Nasense Labs Private Limited by executing a Share Purchase Agreement on August 10, 2026. The deal follows board approval from July 22, 2026, and was disclosed under SEBI Regulation 30. No financial terms were specified in the immediate filing.

NACL Industries Q1 profit rises 65%; EBITDA margin expands to 10.8%

NACL Industries Limited reported a standalone net profit of ₹23.57 crore for Q1FY27, a 64.8% increase from the previous year. EBITDA margin expanded to 10.8% while consolidated net profit rose to ₹20.84 crore. The Board approved the divestment of its stake in Nasense Labs Private Limited for ₹8,15,29,967.

NACL Industries revises MD remuneration at 39th AGM

NACL Industries held its 39th Annual General Meeting on July 22, 2026, approving the audited standalone and consolidated financial statements for FY26. Shareholders passed resolutions to re-appoint Mr. Sankarasubramanian S as Non-Executive Director, ratify cost auditor remuneration for FY27, and revise the remuneration of Dr. Raghuram Devarakonda, MD & CEO. The meeting was conducted via video conferencing under the chairmanship of Mr. Arun Alagappan.

NACL Industries confirms zero share encumbrance in FY26

Coromandel International, promoter of NACL Industries, confirmed no encumbrance on shares in FY26. The filing under SEBI SAST Regulations listed 199 promoter and PAC entities.

NACL Industries 39th AGM on July 22, 2026; FY26 Marks Strong Turnaround

NACL Industries Limited has scheduled its 39th AGM for July 22, 2026, via video conferencing. The meeting agenda includes adopting financial statements for FY26 and revising the MD & CEO's remuneration. FY26 marked a strong turnaround with a net profit of ₹457 Lakhs, supported by a rights issue and credit rating upgrades.

NACL Industries Reports Nil Deviation in Rights Issue Fund Utilization for Q4 FY26

NACL Industries Limited reported nil deviation in the utilization of its Rights Issue proceeds of Rs 24,928.92 lakh for the quarter ended March 31, 2026, as verified by monitoring agency CRISIL Ratings Limited. Funds were deployed towards repayment of borrowings, investment in subsidiary NACL Spec-Chem Limited, and general corporate purposes, with an unutilized balance of Rs 3,079.97 lakh temporarily parked in Axis Bank fixed deposits yielding 4.50% returns. The company allotted 3,25,01,851 Rights Equity Shares on March 31, 2026, and noted a delay in GCP utilization against the offer document schedule.